<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>799</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>12775762</PubmedId>
            <Abstract>Influenza virus-specific CD8+ T cells generally recognize peptides derived from conserved, internal proteins that are not subject to antibody-mediated selection pressure. Prior exposure to any one influenza A virus (H1N1) can prime for a secondary CD8+ T cell response to a serologically different influenza A virus (H3N2). The protection afforded by this recall of established CD8+ T cell memory, although limited, is not negligible. Key characteristics of primary and secondary influenza-specific host responses are probed here with recombinant viruses expressing modified nucleoprotein (NP) and acid polymerase (PA) genes. Point mutations were introduced into the epitopes derived from the NP and PA such that they no longer bound the presenting H2Db MHC class I glycoprotein, and reassortant H1N1 and H3N2 viruses were made by reverse genetics. Conventional (C57BL/6J, H2b, and Ig+/+) and Ig-/- (muMT) mice were more susceptible to challenge with the single NP [HKx31 influenza A virus (HK)-NP] and PA (HK-PA) mutants, but unlike the Ig-/- mice, Ig+/+ mice were surprisingly resistant to the HK-NP/-PA double mutant. This virus was found to promote an enhanced IgG response resulting, perhaps, from the delayed elimination of antigen-presenting cells. Antigen persistence also could explain the increase in size of the minor KbPB1703 CD8+ T cell population in mice infected with the mutant viruses. The extent of such compensation was always partial, giving the impression that any virus-specific CD8+ T cell response operates within constrained limits. It seems that the relationship between protective humoral and cellular immunity is neither simple nor readily predicted.</Abstract>
            <ArticleYear>2003</ArticleYear>
            <ArticlePages>7235-40</ArticlePages>
            <ArticleTitle>Protection and compensation in the influenza virus-specific CD8+ T cell response.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Webby</LastName>
                    <ForeName>Richard J</ForeName>
                </Author>
                <Author>
                    <LastName>Andreansky</LastName>
                    <ForeName>Samita</ForeName>
                </Author>
                <Author>
                    <LastName>Stambas</LastName>
                    <ForeName>John</ForeName>
                </Author>
                <Author>
                    <LastName>Rehg</LastName>
                    <ForeName>Jerold E</ForeName>
                </Author>
                <Author>
                    <LastName>Webster</LastName>
                    <ForeName>Robert G</ForeName>
                </Author>
                <Author>
                    <LastName>Doherty</LastName>
                    <ForeName>Peter C</ForeName>
                </Author>
                <Author>
                    <LastName>Turner</LastName>
                    <ForeName>Stephen J</ForeName>
                </Author>
            </Authors>
            <Affiliations>Department of Infectious Diseases, St. Jude Children's Research Hospital, 332 North Lauderdale, Memphis, TN 38105, USA.</Affiliations>
            <ArticleChemicalList>Antibodies, Viral;Epitopes;Viral Proteins</ArticleChemicalList>
            <ArticleMeshHeadingsList>Agammaglobulinemia(genetics; immunology); Animals; Antibodies, Viral(biosynthesis); CD8-Positive T-Lymphocytes(immunology); Epitopes(genetics); Female; Influenza A virus(genetics; immunology; pathogenicity); Mice; Mice, Inbred BALB C; Mice, Knockout; Mutation; Orthomyxoviridae Infections(genetics; immunology); Recombination, Genetic; Viral Proteins(genetics; immunology)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>100</Volume>
                <Issue>12</Issue>
                <Title>Proceedings of the National Academy of Sciences of the United States of America</Title>
                <Issn>0027-8424</Issn>
                <MedlineTa>Proc Natl Acad Sci U S A</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>PB1 703</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>SSYRRPVGI</LinearSequence>
                        <StartingPosition>703</StartingPosition>
                        <EndingPosition>711</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P03431.2</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>211044</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Page 7236</LocationOfData>
                <EpitopeId>61497</EpitopeId>
                <ReferenceStartingPosition>703</ReferenceStartingPosition>
                <ReferenceEndingPosition>711</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>This epitope is not immunogenic in WT immunizations, but upon mutation in immunodominant epitopes PA224 and NP366 of source species, it becomes immunogenic. PB1 stands for Polymerase basic 1 protein, also known as RNA-directed RNA polymerase subunit P1.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figures 3C and 4C</LocationOfData>
                        <TCellId>8510</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                                <Sex>F</Sex>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>211044</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>2 immunizations, the 1st with source species (10&lt;sup&gt;8&lt;/sup&gt; ID50 i.p), and 8 wk. later challenged with HKx31 (10&lt;sup&gt;5&lt;/sup&gt; to 10&lt;sup&gt;6&lt;/sup&gt; ID50) virus intranasally.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Depending on the dose of challenge, tissue obtained at different time points is analyzed.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <MhcAllele>
                            <MhcAlleleId>122</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>PB1 703</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>SSYRRPVGI</LinearSequence>
                                        <StartingPosition>703</StartingPosition>
                                        <EndingPosition>711</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P03431.2</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>211044</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>47</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>At several time points after challenge with HK strain Influenza A viruses with mutant NP366 and PA224 immunodominant epitopes (either as single or double mutant) of mice previously infected with a corresponding mutant PR strain, significant numbers of peptide specific CD8+ cells are obtained, while the inoculation with wild-type strains, expressing the immunodominant epitopes, precludes the proliferation of CD8+ cells directed against this epitope. Similar results are seen in bronchoalveolar lymphocytes (BAL).</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>NP366</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>ASNENMETM</LinearSequence>
                        <StartingPosition>366</StartingPosition>
                        <EndingPosition>374</EndingPosition>
                        <SourceMolecule>
                            <IedbAccession>SRC124</IedbAccession>
                        </SourceMolecule>
                        <SourceOrganismId>211044</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Page 7236</LocationOfData>
                <EpitopeId>4602</EpitopeId>
                <ReferenceStartingPosition>366</ReferenceStartingPosition>
                <ReferenceEndingPosition>374</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <TCell>
                        <LocationOfData>Figures 3A and 4A</LocationOfData>
                        <TCellId>15958</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                                <Sex>F</Sex>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>211044</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>2 immunizations, the 1st with source species (10&lt;sup&gt;8&lt;/sup&gt; ID50 i.p), and 8 wk. later challenged with HKx31 (10&lt;sup&gt;5&lt;/sup&gt; to 10&lt;sup&gt;6&lt;/sup&gt; ID50) virus intranasally.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Depending on the dose of challenge, tissue obtained at different time points is analyzed.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <MhcAllele>
                            <MhcAlleleId>122</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>NP366</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>ASNENMETM</LinearSequence>
                                        <StartingPosition>366</StartingPosition>
                                        <EndingPosition>374</EndingPosition>
                                        <SourceMolecule>
                                            <IedbAccession>SRC124</IedbAccession>
                                        </SourceMolecule>
                                        <SourceOrganismId>211044</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>47</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>At several time points after challenge with HK strain Influenza A virus (either wild type or mutant for immunodominant epitope PA224) of mice previously infected with the corresponding wild-type or mutant PR strain, significant numbers of peptide specific CD8+ cells are obtained. When immunized with strains harboring mutant forms of this epitope containing N5Q substitution (i.e. lacking MHC binding residue), epitope specific CD8+ cells are not obtained. Similar results are seen in bronchoalveolar lymphocytes (BAL).</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>PA224</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>SSLENFRAYV</LinearSequence>
                        <StartingPosition>224</StartingPosition>
                        <EndingPosition>233</EndingPosition>
                        <SourceMolecule>
                            <IedbAccession>SRC121</IedbAccession>
                        </SourceMolecule>
                        <SourceOrganismId>211044</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Page 7236</LocationOfData>
                <EpitopeId>61151</EpitopeId>
                <ReferenceStartingPosition>224</ReferenceStartingPosition>
                <ReferenceEndingPosition>233</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Also known as RNA-directed RNA polymerase subunit P2.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figures 3B and 4B</LocationOfData>
                        <TCellId>15967</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                                <Sex>F</Sex>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>211044</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>2 immunizations, the 1st with source species (10&lt;sup&gt;8&lt;/sup&gt; ID50 i.p), and 8 wk. later challenged with HKx31 (10&lt;sup&gt;5&lt;/sup&gt; to 10&lt;sup&gt;6&lt;/sup&gt; ID50) virus intranasally.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Depending on the dose of challenge, tissue obtained at different time points is analyzed.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <MhcAllele>
                            <MhcAlleleId>172</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>PA224</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>SSLENFRAYV</LinearSequence>
                                        <StartingPosition>224</StartingPosition>
                                        <EndingPosition>233</EndingPosition>
                                        <SourceMolecule>
                                            <IedbAccession>SRC121</IedbAccession>
                                        </SourceMolecule>
                                        <SourceOrganismId>211044</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>47</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>At several time points after challenge with the HK strain Influenza A virus mutant for epitope NP366 of mice previously infected with the similar mutant PR strain, higher numbers of peptide specific CD8+ cells were obtained than when wild-type prime and challenge virus were used, implying a compensatory response for the lack of response to NP366.  When immunized with strains harboring mutant forms of this epitope containing the N5Q substitution (i.e. lacking MHC binding residue), epitope specific CD8+ cells are not produced. Similar results are seen in bronchoalveolar lymphocytes (BAL).</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

